1045 - What's Next for a New Lyme Vaccine
About this episode
This episode discusses a new Lyme vaccine showing 70% efficacy and the challenges it faces in clinical trials.
About this episode: A new vaccine shows 70% efficacy in preventing Lyme disease, but limitations to the clinical trials put the fate of this intervention in limbo. In this episode: Anna Durbin, an expert in experimental vaccines, explains where this vaccine shows promise, where it falls short, and what could happen next for licensing and regulation. Guest: Dr. Anna Durbin is a professor of International Health and the director of the Johns Hopkins Center for Immunization Research . Host: Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs . Show links and related content: Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial —Pfizer Tickborne Diseases Are on the Rise—Here's What To Know —Johns Hopkins Bloomberg School of Public Health F.D.A. Reverses Decision and Agrees to Review Moderna's Flu Vaccine —New York Times It's Tick Season! —Public Health On Call (April 2025) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile…
More episodes of Public Health On Call
- 1044 - A Peek Behind the Curtain: A Conversation with Our Resident in Residence
- 1043 - How Community Health Workers Improve Research
- 1042 - The Red Hill Water Crisis: How Jet Fuel Contaminated the Water Supply of More Than 60,000 People
- 1041 - World Malaria Day: Promising Tools for Elimination Amidst Research Cuts
- 1040 - Growing Demand for Menopausal Hormone Therapies Brings Excitement—and New Concerns
- 1039 - Spending Down Billions in Opioid Settlement Money: The Debatable, The Inventive, and The Innovative
Explore listener stats, chart rankings, contacts and more on the Public Health On Call podcast page.